Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses

被引:4
|
作者
Xie, Feng [1 ,2 ,5 ]
Zhou, Ting [1 ,3 ]
Humphries, Brittany [1 ]
Neumann, Peter J. [4 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[2] McMaster Univ, Fac Hlth Sci, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[3] China Pharmaceut Univ, Ctr Pharmacoecon & Outcome Res, Nanjing, Peoples R China
[4] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 1280 Main St West, Hamilton, ON L8S 4L8, Canada
关键词
age; cost-effectiveness analysis; elderly; discrimination; quality-adjusted life-year;
D O I
10.1016/j.jval.2024.03.011
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Critics of quality-adjusted life-years argue that it discriminates against older individuals. However, little empirical evidence has been produced to inform this debate. This study aimed to compare published cost-effectiveness analyses (CEAs) on patients aged >= 65 years and those aged <65 years. Methods: We used the Tufts Cost-Effectiveness Analysis Registry to identify CEAs published in MEDLINE between 1976 and 2021. Eligible CEAs were categorized according to age (>= 65 years vs <65 years). The distributions of incremental cost-effectiveness ratios (ICERs) were compared between the age groups. We used logistic regression to assess the association between age groups and the cost-effectiveness conclusion adjusted for confounding factors. We conducted sensitivity analyses to explore the impact of mixed age and age-unknown groups and all ICERs from the same CEAs. Subgroup analyses were also conducted. Results: A total of 4445 CEAs categorized according to age <65 years (n = 3784) and age >= 65 years (n = 661) were included in the primary analysis. The distributions of ICERs and the likelihood of concluding that the intervention was cost-effective were similar between the 2 age groups. Adjusted odds ratios ranged from 1.132 (95% CI 0.930-1.377) to 1.248 (95% CI 0.970-1.606) (odds ratio >1 indicating that CEAs for age >= 65 years were more likely to conclude the intervention was cost-effective than those for age <65 years). Sensitivity and subgroup analyses found similar results. Conclusion: Our analysis found no systematic differences in published ICERs using quality-adjusted life-years between CEAs for individuals aged >= 65 years and those for individuals aged <65 years.
引用
收藏
页码:706 / 712
页数:7
相关论文
共 50 条
  • [1] An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncology
    Raymakers, Adam J. N.
    Rand, Leah Z.
    Feldman, William B.
    Kesselheim, Aaron S.
    JOURNAL OF CANCER POLICY, 2025, 43
  • [2] Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the Bathwater
    Goldstein, Daniel A.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (06) : 500 - 503
  • [3] The use of quality-adjusted life-years in cost-effectiveness studies
    Sculpher, M
    ALLERGY, 2006, 61 (05) : 527 - 530
  • [4] COST-EFFECTIVENESS OF TREATING CRITICAL ISCHEMIA USING QUALITY-ADJUSTED LIFE YEARS
    ALLEN, DR
    FERGUS, MEB
    CHANT, ADB
    BRITISH JOURNAL OF SURGERY, 1990, 77 (03) : A348 - A348
  • [5] Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review
    Rand, Leah Z.
    Kesselheim, Aaron S.
    HEALTH AFFAIRS, 2021, 40 (09) : 1402 - 1410
  • [6] The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review
    Wichmann, Anne B.
    Adang, Eddy M. M.
    Stalmeier, Peep F. M.
    Kristanti, Sinta
    Van den Block, Lieve
    Vernooij-Dassen, Myrra J. F. J.
    Engels, Yvonne
    PALLIATIVE MEDICINE, 2017, 31 (04) : 306 - 322
  • [7] Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery
    McCarthy, Ian
    O'Brien, Michael
    Ames, Christopher
    Robinson, Chessie
    Errico, Thomas
    Polly, David W., Jr.
    Hostin, Richard
    NEUROSURGICAL FOCUS, 2014, 36 (05)
  • [8] A Quality-Adjusted Life Year of Prevention: The Cost-Effectiveness of Nutrition Counseling
    Tsai, Adam Gilden
    JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2011, 111 (01) : 53 - 55
  • [9] Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years
    Hawton, Annie
    Goodwin, Elizabeth
    Boddy, Kate
    Freeman, Jennifer
    Thomas, Sarah
    Chataway, Jeremy
    Green, Colin
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (03) : 346 - 351
  • [10] Cost-effectiveness of losartan in patients with hypertension and left ventricular hypertrophy: cost per quality-adjusted life years gained in the LIFE trial
    Jonsson, B
    Carides, GW
    Burke, TA
    Dasbach, EJ
    Lindholm, LH
    Dahlof, B
    EUROPEAN HEART JOURNAL, 2004, 25 : 331 - 331